Thaynara Ramalho Santos

Mrs. Thaynara Ramalho Santos


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FFFelipe Rodrigues Silva Felipe
Felipe Rodrigues Silva Felipe
EJEdson Tobias De Jesus
Edson Tobias De Jesus
MSMAYARA - CAMPUS SAO LUIS MONTE SÁ
MAYARA - CAMPUS SAO LUIS MONTE SÁ
MDMargaret Dawson
Margaret Dawson
TSThaynara Ramalho Santos
Thaynara Ramalho Santos
GSGilmar Silverio da Silva
Gilmar Silverio da Silva
Background/Objectives: The growing threat of antimicrobial resistance (AMR) has inten-sified the search for innovative antimicrobial materials. Herein, we synthesized and characterized zinc bismuthate-based nanocomposites (ZB1 and ZB4) and investigated their antimicrobial efficacy against two Gram-positive bacteria (Staphylococcus aureus and Corynebacterium diphtheriae), one Gram-negative bacterium (Klebsiella pneumoniae), and two fungal pathogens (Cryptococcus neoformans and Candida albicans). Toxicity was further as-sessed using Tenebrio molitor larvae as an alternative model. Methods: Nanocomposites were prepared via a hydrothermal process and characterized using X-ray diffraction (XRD), Raman spectroscopy, Zeta potential, and high-resolution transmission electron microscopy (HR-TEM). Antimicrobial activity was evaluated through disk diffusion as-says coupled with minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) assessments. Results: ZB1 and ZB4 inhibited S. aureus (10.7 ± 1.2 mm and 11.3 ± 1.2 mm), C. diphtheriae (10.7 ± 1.1 mm and 11.3 ± 1.1 mm), and C. neoformans (10.7 ± 1.1 mm and 11.7 ± 2.9 mm), while no inhibition was observed for C. albicans and K. pneumoniae. From MIC and MFC evaluations, ZB1 was effective up to 1000 μg/mL, and ZB4 up to 500 μg/mL. Toxicity assays revealed survival rates of 70% for ZB1 and 60% for ZB4, with no statistically significant differences compared to the control (p = 0.156). Notably, ZB4 is a promising candidate due to its enhanced antimicrobial performance and moderate toxicity. Conclusions: Our findings highlight ZB1 and ZB4 nanocomposites as promising antimicrobial agents, offering new avenues in nanotechnology-driven healthcare solutions aimed at tackling antimicrobial resistance.